Someone else brought up what I had been thinking.... it would be a grave mistake to not unblind date if pvalue is not met at interim. We’re in a pandemic while there is as large as unmet need as the FDA has ever seen. We should not only be able to receive EUA for whatever percentage mortality reduction we show, in addition I believe we will show clinical and statistical significance on several secondary endpoints. Holding back this drug for a full approval 3 months from now is not the right answer. Just thinking out loud as I think the pvalue will be real close for Approval at interm.